Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02414841 · ClinicalTrials.gov registry record · Phase 3
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
A Phase 3 study, sponsored by Proteon Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 696
- Enrollment target
NCT02414841 is a Phase 3 study that has completed, run by Proteon Therapeutics. The registered enrollment target is 696 participants.
The verdict
NCT02414841, a Phase 3 study, has completed, sponsored by Proteon Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 696 participants
- Enrollment target
Study Summary
This research study is designed to assess the safety and effectiveness of an experimental drug called vonapanitase (PRT-201) in patients both receiving or expecting to receive hemodialysis who have chronic kidney disease and who are undergoing surgery to create a new access point to their bloodstream for hemodialysis. Vonapanitase is a protein that has been shown in previous research studies to help keep vessels patent when applied to the outside surface of the blood vessels (arteries and veins) in patients who undergo surgery to create an arteriovenous fistula (AVF). The purpose of this study is to determine whether vonapanitase when applied to a limited segment of your blood vessel (about 2 inches) immediately after surgery is safe and improves the patency of your AVF.
Interventions
- DRUG Placebo
- DRUG Vonapanitase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 696 participants |
| Start Date | 2015-08 |
| Est. Completion | 2019-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02414841
The ClinicalTrials.gov registry entry for NCT02414841 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 696 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Proteon Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02414841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02414841 about?
NCT02414841 is a clinical study titled "A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)". This research study is designed to assess the safety and effectiveness of an experimental drug called vonapanitase (PRT-201) in patients both receiving or expecting to receive hemodialysis who have chronic kidney disease and who are undergoing surgery to create a new access point to their bloodstrea...
What is the current status of trial NCT02414841?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 696 participants. The study started on 2015-08. Estimated completion is 2019-05-01.
What interventions are being tested in trial NCT02414841?
The interventions under investigation include: Placebo (DRUG), Vonapanitase (DRUG).
Who is sponsoring clinical trial NCT02414841?
This trial is sponsored by Proteon Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.